Uncategorized
Omeros Corporation Reports First Quarter 2018 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include: 1Q 2018 total and OMIDRIA® revenues were $1.6 million, compared to $12.3 million in 1Q 2017; the decrease is the result of the scheduled expiration of OMIDRIA pass-through reimbursement status on January 1, 2018. The Consolidated Appropriations Act, signed into law in March 2018, includes a provisio